In a multinational phase 3 trial, researchers evaluated the efficacy and safety of tarlatamab in patients with relapsed small-cell lung cancer after platinum-based chemotherapy. Tarlatamab significantly prolonged overall survival, progression-free survival, and tumor response rates compared to standard chemotherapy, with fewer high-grade toxicities. It represents a potential second-line treatment option for these patients, including those with platinum resistance or brain metastases.

Source: NEJM